آثار عقار أولانزابين على مستوى سكر الدم وضغط الدم والدهون في عينة من مرضى الفصام في العراق

Chen Y, Wang Y, Fang X, Zhang Y, Song L, Zhang C. Association of the HTR2C-759C/T polymorphism and antipsychotic-induced weight gain: a meta-analysis. Gen Psychiatr. 2020;33(3):e100192. doi: 10.1136/gpsych-2020-100192. DOI: https://doi.org/10.1136/gpsych-2020-100192

Gupta A, Jadhav A, Dubey V. Comparison of serum lipid profile changes during treatment of olanzapine and risperidone. Int J Life-Sci Sci Res. 2017;3(5):1283-1286. DOI: https://doi.org/10.21276/ijlssr.2017.3.5.3

Jackson M, Delp C, Bindschadler D, Sarrel M, Wollaeger R, Lam D. Dynamic gate product and artifact generation from system models. IEEE J. 2011;11944045:1-10. doi: 10.1109/AERO.2011.5747541. DOI: https://doi.org/10.1109/AERO.2011.5747541

Mednova IA, Kornetova EG, Ivanovа SA. Model for predicting metabolic syndrome in patients with paranoid schizophrenia. Siberian Herald Psychiatr Addict Psychiatr. 2020;3(108):45-50. doi: 10.26617/1810-3111-2020-3(108)-45-50. DOI: https://doi.org/10.26617/1810-3111-2020-3(108)-45-50

Su KP, Wu PL, Pariante CM. A crossover study on lipid and weight changes associated with olanzapine and risperidone. Psychopharmacology (Berl). 2005;183(3):383-386. doi: 10.1007/s00213-005-0205-2. DOI: https://doi.org/10.1007/s00213-005-0205-2

Saddichha S, Vishnuvardhan G, Akhtar S. Obesity, diabetes and hypertension associated with antipsychotic use in remitted schizophrenia. Int J Risk Saf Med. 2011;23(3):181-185. doi: 10.3233/JRS-2011-0536. DOI: https://doi.org/10.3233/JRS-2011-0536

Dayabandara M, Hanwella R, Ratnatunga S, Seneviratne S, Suraweera C, de Silva VA. Antipsychotic-associated weight gain: management strategies and impact on treatment adherence. Neuropsychiatr Dis Treat. 2017;13:2231-2241. doi: 10.2147/NDT.S113099. DOI: https://doi.org/10.2147/NDT.S113099

Al-Thanoon ZA, Mahmood IH. Metabolic changes caused by first generation antipsychotic versus second generation antipsychotic in schizophrenic patients. J Pharm Rese. 2013;7(6):468–471. doi: 10.1016/j.jopr.2013.06.016. DOI: https://doi.org/10.1016/j.jopr.2013.06.016

Mandrioli R, Protti M, Mercolini L. Metabolic syndrome in schizophrenia: Focus on the role of antipsychotic medications and indications for therapeutic drug monitoring (TDM) methods. Front Clin Drug Res Diabetes Obes. 2020;5:1-65. DOI: https://doi.org/10.2174/9781681087535120050003

American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-5-TR). Washington, DC; 2013. DOI: https://doi.org/10.1176/appi.books.9780890425596

Kasanin J. The blood sugar curve in mental disease. Arch NeurPsych. 1926;16(4):414-419. doi:10.1001/archneurpsyc.1926.02200280022002. DOI: https://doi.org/10.1001/archneurpsyc.1926.02200280022002

Liu JH, Chen N, Guo YH, Guan XN, Wang J, Wang D, et al. Metabolomics-based understanding of the olanzapine-induced weight gain in female first-episode drug-naïve patients with schizophrenia. J Psychiatr Res. 2021;140:409-415. doi: 10.1016/j.jpsychires.2021.06.001. DOI: https://doi.org/10.1016/j.jpsychires.2021.06.001

Kinon BJ, Basson BR, Gilmore JA, Tollefson GD. Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. J Clin Psychiatry. 2001;62(2):92-100. PMID: 11247108. DOI: https://doi.org/10.4088/JCP.v62n0204

Woo YS, Kim W, Chae JH, Yoon BH, Bahk WM. Blood pressure changes during clozapine or olanzapine treatment in Korean schizophrenic patients. World J Biol Psychiatry. 2009;10(4 Pt 2):420-425. doi: 10.1080/15622970801910399. DOI: https://doi.org/10.1080/15622970801910399

Mozes T, Greenberg Y, Spivak B, Tyano S, Weizman A, Mester R. Olanzapine treatment in chronic drug-resistant childhood-onset schizophrenia: an open-label study. J Child Adolesc Psychopharmacol. 2003;13(3):311-317. doi: 10.1089/104454603322572642. DOI: https://doi.org/10.1089/104454603322572642

Lindenmayer JP, Czobor P, Volavka J, Citrome L, Sheitman B, McEvoy JP, et al. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry. 2003;160(2):290-296. doi: 10.1176/appi.ajp.160.2.290. DOI: https://doi.org/10.1176/appi.ajp.160.2.290

McEvoy JP, Lieberman JA, Perkins DO, Hamer RM, Gu H, Lazarus A, et al. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry. 2007;164(7):1050-1060. doi: 10.1176/ajp.2007.164.7.1050. DOI: https://doi.org/10.1176/ajp.2007.164.7.1050

Koro CE, Fedder DO, L'Italien GJ, Weiss SS, Magder LS, Kreyenbuhl J, et al. Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. BMJ. 2002;325(7358):243. doi: 10.1136/bmj.325.7358.243. DOI: https://doi.org/10.1136/bmj.325.7358.243

Ratzoni G, Gothelf D, Brand-Gothelf A, Reidman J, Kikinzon L, Gal G, et al. Weight gain associated with olanzapine and risperidone in adolescent patients: a comparative prospective study. J Am Acad Child Adolesc Psychiatry. 2002;41(3):337-343. doi: 10.1097/00004583-200203000-00014. DOI: https://doi.org/10.1097/00004583-200203000-00014

Ghaeli P, Dufresne RL. Serum triglyceride levels in patients treated with clozapine. Am J Health Syst Pharm. 1996;53(17):2079-2081. doi: 10.1093/ajhp/53.17.2079.. DOI: https://doi.org/10.1093/ajhp/53.17.2079

Leard-Hansson J, Guttmacher L. Antipsychotic-associated weight gain. Clin Psychiat News. 2005;33(6):23. DOI: https://doi.org/10.1016/S0270-6644(05)70424-0

Clark ML, Ray TS, Paredes A, Ragland RE, Costiloe JP, Smith CW, et al. Chlorpromazine in women with chronic schizophrenia: the effect on cholesterol levels and cholesterol-behavior relationships. Psychosom Med. 1967;29(6):634-642. doi: 10.1097/00006842-196711000-00008. DOI: https://doi.org/10.1097/00006842-196711000-00008

Lee JS, Kwon JS, Kim D, Kim S-W, Kim J-J, Kim J-H, et al. Prevalence of Metabolic Syndrome in Patients with Schizophrenia in Korea: A Multicenter Nationwide Cross-Sectional Study. Psychiatr Invest. 2017;14(1):44. doi: 10.4306/pi.2017.14.1.44. DOI: https://doi.org/10.4306/pi.2017.14.1.44

Eder U, Mangweth B, Ebenbichler C, Weiss E, Hofer A, Hummer M, et al. Association of olanzapine-induced weight gain with an increase in body fat. Am J Psychiatry. 2001;158(10):1719-1722. doi: 10.1176/appi.ajp. DOI: https://doi.org/10.1176/appi.ajp.158.10.1719

Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, et al. Antipsychotic-induced weight gain: A comprehensive research synthesis. Am J Psychiatry. 1999;156(11):1686-1696. doi: 10.1176/ajp.156.11.1686. DOI: https://doi.org/10.1176/ajp.156.11.1686

Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Curr Opin Cardiol. 2006;21(1):1-6. doi: 10.1097/01.hco.0000200416.65370.a0. DOI: https://doi.org/10.1097/01.hco.0000200416.65370.a0

Maslov B, Babić D, Zovko N. Ipact of psychopharmaca on the frequency of metabolic syndrome in patients with schizophrenia. Psychiatria Danubina. 2009;21(1):137.

Pandya S. Antipsychotics: uses, actions and prescribing rationale. Nurse Prescrib. 2009;7(1):23-27. doi: 10.12968/npre.2009.7.1.38630. DOI: https://doi.org/10.12968/npre.2009.7.1.38630